2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1639

Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1647

Uveitis, the Most Faithful Partner of Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1673

Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1378

Validation of a Spanish Version of the Functional Index for Hand Osteoarthritis (FIHOA)

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1540

Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1712

Validation of Proposed EULAR/Acr SLE Classification Criteria Versus SLICC SLE Classification Criteria

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1338

Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1635

Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1484

Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1683

Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1060

Variation in the Synovial Fluid Metabolome According to Disease Activity in Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1794

Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1731

Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1557

Visualization of Dorsal Root Ganglionitis with Three-Tesla Magnetic Resonance Neurography in Sensory Ataxic Neuropathy Associated with Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1273

What Did Patients from the US Think about Their Gout in 2017?

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].